Assembly Biosciences (NASDAQ:ASMB) Lifted to “Sell” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a strong sell rating to a sell rating in a research report report published on Wednesday, September 18th, BidAskClub reports.

Several other brokerages also recently commented on ASMB. ValuEngine upgraded Assembly Biosciences from a hold rating to a buy rating in a research note on Thursday, August 8th. Zacks Investment Research upgraded Assembly Biosciences from a hold rating to a buy rating and set a $13.00 target price on the stock in a research note on Tuesday, September 17th. William Blair reiterated a buy rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. Finally, Chardan Capital restated a hold rating and issued a $30.00 price target on shares of Assembly Biosciences in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Assembly Biosciences has an average rating of Buy and a consensus price target of $29.33.

ASMB traded up $0.24 during midday trading on Wednesday, reaching $8.71. 133,390 shares of the company’s stock traded hands, compared to its average volume of 344,246. The firm has a fifty day moving average of $11.23 and a two-hundred day moving average of $14.12. The stock has a market capitalization of $214.95 million, a price-to-earnings ratio of -2.19 and a beta of 1.46. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.20 and a quick ratio of 9.20. Assembly Biosciences has a 52 week low of $8.13 and a 52 week high of $27.60.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.41. Assembly Biosciences had a negative return on equity of 46.33% and a negative net margin of 622.25%. The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $3.90 million. Sell-side analysts forecast that Assembly Biosciences will post -3.64 EPS for the current year.

A number of institutional investors have recently made changes to their positions in ASMB. BNP Paribas Arbitrage SA raised its holdings in Assembly Biosciences by 87,340.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 4,367 shares during the period. Victory Capital Management Inc. boosted its position in shares of Assembly Biosciences by 5.9% during the first quarter. Victory Capital Management Inc. now owns 562,399 shares of the biopharmaceutical company’s stock valued at $11,074,000 after buying an additional 31,490 shares during the period. Private Advisors LLC boosted its position in shares of Assembly Biosciences by 17.9% during the first quarter. Private Advisors LLC now owns 17,724 shares of the biopharmaceutical company’s stock valued at $349,000 after buying an additional 2,688 shares during the period. Marshall Wace North America L.P. boosted its position in shares of Assembly Biosciences by 191.5% during the first quarter. Marshall Wace North America L.P. now owns 4,431 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 2,911 shares during the period. Finally, FMR LLC raised its stake in shares of Assembly Biosciences by 0.6% during the first quarter. FMR LLC now owns 445,716 shares of the biopharmaceutical company’s stock valued at $8,776,000 after acquiring an additional 2,680 shares in the last quarter. 81.94% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: How to Trade Using Analysts Ratings

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.